Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PPID | Q08752 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036292 | 0.88 | SIRT2 (0.41) | SIRT2FAAHALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL312947 | 0.86 | SIRT2 (0.39) | SIRT2ALDH1A1 | |
| SCHEMBL5790406 | 0.84 | SIRT2 (0.43) | SIRT2SMN1; SMN2 | |
| SCHEMBL1312709 | 0.84 | SIRT2 (0.39) | SIRT2 | |
| SCHEMBL5060964 | 0.81 | LMNA (0.40) | SIRT2 | |
| SCHEMBL10664135 | 0.80 | SIRT2 (0.41) | SIRT2SMN1; SMN2 | |
| SCHEMBL10457235 | 0.79 | SIRT2 (0.37) | SIRT2 | |
| SCHEMBL6777569 | 0.78 | SIRT2 (0.48) | SIRT2ALDH1A1 | |
| SCHEMBL9518110 | 0.78 | FLT3 (0.39) | SIRT2ALDH1A1 | |
| SCHEMBL1668519 | 0.77 | TOP2A (0.41) | SIRT2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| EP-1681290-B9 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1471056-B1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-8093403-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-1681290-B1 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2011-10-27 | — | — | US | disclosed |
| EP-2275411-A2 | Reformatsky Reagent in Stable Form and Process for Producing the Same | Takeda Pharmaceutical Company Limited (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-7662974-B2 | reduction of carboxylic acid ester using metal hydride complexes and metal halides to form compounds such as ethyl (3S)-3-hydroxy-3-{6-[(methylamino)carbonyl]-2-naphthyl}-3-(1-trityl-1H-imidazol-4-yl)propanoate, used as lyase enzyme inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-16 | — | — | US | disclosed |
| US-7141598-B2 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2006-11-28 | — | — | US | disclosed |
| EP-1681290-A2 | Imidazole derivatives, production method thereof and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2006-07-19 | — | — | EP | disclosed |
| EP-1334106-B1 | IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-20050043544-A1 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1471056-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-20040033935-A1 | Novel imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1334106-A2 | NOVEL IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002040484-A2 | NOVEL IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | SIRT2 3756/4885FAAH 2812/4885ALDH1A1 1252/4885 |
| US-20040033935-A1 | Novel imidazole derivatives, production method thereof and use thereof | CYP17A1, CYP21A2, CYP19A1 | SIRT2 2146/4885FAAH 1974/4885ALDH1A1 227/4885 |
| US-20050043544-A1 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | CYP17A1, HSD17B7, HSD17B1 | SIRT2 3753/4885FAAH 2787/4885ALDH1A1 1246/4885 |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, NTRK1, PRKDC | SIRT2 4191/4885FAAH 948/4885ALDH1A1 3884/4885 |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | SIRT2 3756/4885FAAH 2812/4885ALDH1A1 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.